Subscribe
Be the first with the news that moves the market- Sirona Biochem (SBM) will be presenting its latest anti-aging technology, TFC-1326, at the upcoming BIO International 2023 conference in Boston
- The conference, which is the largest gathering worldwide for the biotech industry, will take place from June 5-8, 2023
- TFC-1326 is also a potent antioxidant and anti-inflammatory agent, which helps prevent further signs of aging
- Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology
- Sirona Biochem Corp. (SBM) opened trading at C$0.125 per share
Sirona Biochem (SBM) will be presenting its latest anti-aging technology, TFC-1326, at the upcoming BIO International 2023 conference in Boston.
The conference, which is the largest gathering worldwide for the biotech industry, will take place from June 5-8, 2023. Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer, will present the company’s latest technology.
About anti-aging technology
The company reports that its TFC-1326 is a revolutionary anti-aging compound that has demonstrated exceptional results in recent clinical studies.
It is based on Sirona Biochem’s proprietary platform technology. It employs a novel approach to addressing the underlying causes of aging. When used in a facial cream, TFC-1326 rejuvenates aged skin, increasing density, tightening, reducing sagging, and boosting radiance.
TFC-1326 is also a potent antioxidant and anti-inflammatory agent, which helps prevent further signs of aging. TFC-1326 can be a stand-alone product for anti-aging or an adjunctive option to Botox and dermal filler treatments depending on consumer goals.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. It specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety.
Sirona Biochem Corp. (SBM) opened trading at C$0.125 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
